Introduction
In Sweden about 50% of all drugs are prescribed by GPs. 1 These GPs obtain most of their information on drug treatment from pharmaceutical companies. 2 With rising drug-costs more producer-independent information has been requested. In a Cochrane review on educational outreach visits the authors concluded that these appear to be a promising approach to modifying health professionals' behaviour, especially prescribing. 3 In another review of the effect of continuing medical education (CME) strategies where studies from 1974 to 1994 were evaluated the authors concluded that effective CME such as systematic practice-based interventions and outreach visits are seldom used compared with less effective methods such as conferences. 4 Of later studies on educational interventions in family practice some have [5] [6] [7] and some have not 8, 9 shown improvements in outcome measures. Studies that measured the GPs' knowledge after educational intervention have shown positive effects. 6, 10 Benzodiazepines (BDZ) are widely used and their use is highest among the elderly. 11 In southern Sweden (Skå ne) patients 65 years and older use 84.2 defined daily doses (DDD)/1000 inhabitants compared with 27.4 DDD/1000 inhabitants for all age groups. 12 BDZ have a wide range of CNS effects such as sedation, drowsiness, memory difficulties and lack of coordination. 13, 14 The elderly experience excessive sedation from BDZ compared with younger individuals. 13 In a study on 308 patients with suspected dementia, dementia was attributed in 13 patients to chronic treatment with a single BDZ. 15 The prolonged half-life of many BDZ in the elderly increases the risk of accumulation, which could cause the serum concentration to reach a level where a delirium is induced. 16 The strongest evidence for BDZ-related impaired cognition in the elderly is from a study that documented the improvement of cognitive deficits upon drug withdrawal. 15 According to one study of more than 400 hospitalised patients the relative risk of developing cognitive impairment was 3.5 (95% CI: 1.4-8.8) for those who reported taking BDZ in daily doses equivalent to 5 mg or more of diazepam. 17 Reducing BDZ use by elderly patients is important for several reasons. BDZ use by elderly patients is not only associated with cognitive side effects, 13, 14 but also increases the risk of hip fractures. 18 According to an American study treatment with BDZ appears to increase the risk of hip fractures even at modest doses. 18 These fractures lead to hospitalisation costs. In a European study it was estimated that costs of accidental injuries related to BDZ use in the EU varied between Euro 1.5 and 2.2 billion each year. More than 90% of these costs were in the elderly with fractures as the major contributor. 19 Antipsychotic drugs are often used for the treatment of behavioural symptoms in demented persons. 16 These drugs are associated with several adverse effects, such as extrapyramidal and anticholinergic effects including delirium. 11, 20 Antipsychotic drugs have long been reported to cause delirium. Blockade of a-receptors is a common effect among these drugs, can cause orthostatic reactions, which further increase the risk. 16 All traditional antipsychotic drugs have been reported to increase the risk of delirium. 21 In one study on patients who were transferred from the psychiatric ward to the medical ward because of delirium, 31% of cases were due to low-potency antipsychotic agents. 22 The aim of this study was to evaluate whether educational outreach visits to GP practices can affect the prescribing of BDZ and antipsychotic drugs to the elderly and to evaluate the opinions of the participating GPs towards such education.
Material and methods

Subjects and practices
The committee for research ethics at the University of Lund gave their approval to the study. Each GP gave his or her informed consent to participation. All (41) GP practices in two districts of the county of Skå ne in the south of Sweden were offered group-education programmes on ''drug treatment that may cause confusion in the elderly'' by a physician (PM) and a pharmacist (Å B). Among the 15 GP practices that accepted eight were randomised to active education and seven to control group (Fig. 1) . Characteristics of the practices are described in Table 1 . For the active group the group-education was held two times at each centre from October-December 2000. The prescribing of BDZ and antipsychotic drugs was then monitored during the period October 1, 2000-December, 2001 for the active and the control groups. The control group participated in the education after the study period.
Outreach visit
The physician and the pharmacist visited each practice twice with an interval of 2-8 weeks. The first meeting dealt with different causes of confusion in the elderly.
Flow Diagram
Eligible GP practices n=41 15 GP practices accepted invitation 54 GPs, median 4 per practice (range [1] [2] [3] [4] [5] [6] 26 GP practices chose not to participate 8 GP practices randomised to active group 23 GPs, median 3 per practice (range 1-4) 7 GP practices randomised to control group, 31 GPs, median 5 per practice (range 2-6)
FIGURE 1 Flow diagram
Prescribing BDZ and antipsychotic drugs to the elderly These causes included medications but also other reasons e.g. infections and other illnesses. Literature as well as actual cases were discussed. The second meeting dealt with the effects of BDZ and psychotropic drugs in the elderly. Special attention was drawn to the risks of BDZ with medium-or long-acting duration of action. Medium-acting BDZ prescribed in Sweden are alprazolam, nitrazepam and flunitrazepam whereas diazepam is the only long-acting BDZ. The main message was that these drugs only should be used in the elderly after the potential disadvantages have been considered. We did however stress that it is not easy to withdraw long-term therapies. If trying to do so we recommended thorough evaluation of the effects. There were no discussions about what prescribing was going to be measured or when. Actual cases were discussed and commented on. After the second visit the physicians' opinions were evaluated using an anonymous questionnaire. The questionnaire consisted of six questions that could be answered by selecting a number on a scale of 1-10, where 1 mean strongly disagree and 10 mean strongly agree ( Table 2 ). The questionnaire was constructed based on a questionnaire used in a similar study. 6 The opinions were evaluated both in the active and the control groups.
Data collection and statistical analysis Prescription data were collected from Apoteket AB (National Corporation of Swedish Pharmacies) measured as DDD dispensed during 3-month periods from October 2000 until December 2001. In Sweden prescriptions often last 1 year and many patients have a yearly check-up by their GP. We wanted to investigate if prescriptions were affected 1 year after the educational outreach visit. We intended to do follow-up on the long-term effects of our educational outreach visits. However, after June 2002 there was a change in the way prescribing-statistics are collected by Apoteket AB making it impossible to compare data before and after June 2002. There are no data on prescription for individual GPs but only for all GPs working at a specific practice. We compared logarithmically transformed ratios of mean values, for each practice, of prescriptions (DDD) at each 3-month period after the intervention over the prescriptions during the first 3-month period, October-December 2000. The analyses were performed using a mixed model with the group by period interaction as fixed effects and practices as random effects using SAS proc mixed (ver 8.2, SAS Institute, Cary, NC, USA). Differences of the least square mean estimates between the two groups, and their confidence limits, were calculated for each period. The results are presented as geometric means and confidence intervals.
Results
Characteristics of the practices
The participating practices were situated in villages or small towns except one in the control group that was in a city of 100 000 inhabitants. The centres were all publicly financed. The number of GPs varied from one to six across the practices (Table 1) .
Prescription
One year after the educational outreach visits there was a decrease in prescribing of medium-and long-acting benzodiazepines (25.80%) and total BDP (26.63%) in the active group compared with the control group. These decreases were significant, P < 0.05 (Table 3) . There were significant decreases after 9 months but not after 3 months or 6 months. For antipsychotic drugs there were no significant differences between active and control group.
Opinions of GPs
The opinions of GPs on the educational programmes in this study were overall positive ( Table 2 ). The participating physicians in general agreed with the statements that this education was relevant to their clinical work and that it improved their knowledge.
Discussion
We targeted our intervention to decrease prescribing of BDZ and antipsychotic drugs to elderly patients in general practice since these drugs could cause these patients many problems. For BDZ we succeeded. Since the use of BDZ is a risk factor for cognitive impairment and fractures, the reduction of these drugs among the elderly may have had positive health effects for these elderly patients. Our educational outreach visits did not, however, affect prescribing of antipsychotic drugs. This could be due to different reasons. Antipsychotic Family Practice-an international journal drugs are not prescribed by GPs in the same quantities as BDZ, 12 therefore it is harder to detect any significant changes due to the educational programme. Since the number of prescriptions of antipsychotic drugs is low our study may not have had enough power to detect a difference in contrast to the prescribing of benzodiazepines. In Sweden patients often receive prescriptions for 1 year. Any effect of an intervention is not registered until a patient uses the new prescription. That means that any changes in the prescribing behaviour will not have an immediate effect on prescribing statistics. This is the reason for our measuring dispensed medications 1 year after the intervention. We intended to measure long-term (2 years) effects of educational outreach visits on GPs' prescribing habits. In Sweden there was a change in the way prescribing statistics were collected from the autumn of 2002. Therefore, we could not measure any long-term effects.
In this study there are rather few participating practices and they were randomised to either active or control group. They are all localized in the same districts and we have no reasons to believe that there are any differences between practices in active and control group that may have affected the results.
We have not examined the cost effectiveness of this education programme but as stated previously the use of BDZ is associated with great hospitalisation costs. The physicians in our study chose to participate in this study. A method like this can of course only succeed among physicians willing to participate in the education programme. Educational outreach visits cannot be forced on anyone.
The GPs were overall positive towards this kind of education. These results are comparable to those in an Australian study on educational programmes. 6 As stated previously GPs in Sweden obtained most of their information on drug treatments from pharmaceutical companies. This might explain their positive attitude towards producer-independent education. We also believe that educational outreach visits can be a favoured method since they are convenient for the GPs. In Sweden the authorities and the pharmaceutical companies recently have agreed on stricter regulations on educational programmes offered by the pharmaceutical companies.
In order to attract all interested we offered all participants the same education. The control group in our study also participated in the education although after the study period.
After 2002 when the prescribing statistics (due to new EAN-codes on prescriptions) changed it is only possible to prescribe medium-and long-acting BDZ for 3 months and these drugs can only be prescribed by a physician using a special personal prescription. This is one way that the authorities in Sweden try to influence the prescribing of BDZ in the same direction as we TABLE 2 GPs' opinions on the educational outreach visits (active and control). Scale 1-10 where 1 means strongly disagree and 10 strongly agree (n=54) intended with our educational outreach visits. Other educational programmes have been successful in modifying the prescribing of psychoactive drugs in nursing homes without adversely affecting the overall behaviour and level of functioning of the residents. 23 Of educational outreach visits aimed at reducing BDZ some have 24 succeeded whereas others have not. 25 In this study we have shown that educational outreach visits are well appreciated by GPs and could influence their prescribing habits. This could thus be one way to reduce suffering and costs due to the use of BDZ by elderly patients. We do not know if our method is the best intervention. We welcome studies that compare the outcome of different educational methods.
